SARS-CoV-2-antibody response in health care workers after vaccination or natural infection in a longitudinal observational study.
Anti-SARS-CoV-2-IgG-antibodies
AstraZeneca
BioNTech
Health Care worker
Seroprevalence
Vaccination
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
21 01 2022
21 01 2022
Historique:
received:
07
08
2021
revised:
23
10
2021
accepted:
28
11
2021
pubmed:
14
12
2021
medline:
18
1
2022
entrez:
13
12
2021
Statut:
ppublish
Résumé
Following a year of development, several vaccines have been approved to contain the global COVID-19 pandemic. Real world comparative data on immune response following vaccination or natural infection are rare. We conducted a longitudinal observational study in employees at a secondary care hospital affected by the COVID-19 pandemic. Comparisons were made about the presence of anti-SARS-CoV-2 immunglobulin G (IgG) antibody ratio after natural infection, or vaccination with one or two doses of BioNTech/Pfizer (BNT162b2), or one dose of AstraZenca (Vaxzevria) vaccine. We found a 100% humoral response rate in participants after 2 doses of BNT162b2 vaccine. The antibody ratio in participants with one dose BNT162b2 and Vaxzevria did not differ significantly to those with previous PCR-confirmed infection, whereas this was significantly lower in comparison to two doses of BioNTech/Pfizer. We could not identify a correlation with previous comorbidities, obesity or age within this study. Smoking showed a negative effect on the antibody response (p = 0.006) CONCLUSION: Our data provide an overview about humoral immune response after natural SARS-CoV-2 infection or following vaccination, and supports the usage of booster vaccinations, especially in patients after a natural SARS-CoV-2 infection.
Sections du résumé
BACKGROUND
Following a year of development, several vaccines have been approved to contain the global COVID-19 pandemic. Real world comparative data on immune response following vaccination or natural infection are rare.
METHODS
We conducted a longitudinal observational study in employees at a secondary care hospital affected by the COVID-19 pandemic. Comparisons were made about the presence of anti-SARS-CoV-2 immunglobulin G (IgG) antibody ratio after natural infection, or vaccination with one or two doses of BioNTech/Pfizer (BNT162b2), or one dose of AstraZenca (Vaxzevria) vaccine.
RESULTS
We found a 100% humoral response rate in participants after 2 doses of BNT162b2 vaccine. The antibody ratio in participants with one dose BNT162b2 and Vaxzevria did not differ significantly to those with previous PCR-confirmed infection, whereas this was significantly lower in comparison to two doses of BioNTech/Pfizer. We could not identify a correlation with previous comorbidities, obesity or age within this study. Smoking showed a negative effect on the antibody response (p = 0.006) CONCLUSION: Our data provide an overview about humoral immune response after natural SARS-CoV-2 infection or following vaccination, and supports the usage of booster vaccinations, especially in patients after a natural SARS-CoV-2 infection.
Identifiants
pubmed: 34895938
pii: S0264-410X(21)01555-3
doi: 10.1016/j.vaccine.2021.11.081
pmc: PMC8639476
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
206-212Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Lancet Infect Dis. 2021 Jul;21(7):939-949
pubmed: 33930320
Vaccine. 1994 Jul;12(9):771-2
pubmed: 7975854
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
Euro Surveill. 2021 Feb;26(6):
pubmed: 33573712
Clin Infect Dis. 2021 Dec 6;73(11):2065-2072
pubmed: 33906236
Eur J Pharmacol. 2021 Feb 5;892:173751
pubmed: 33245898
Diabetes Metab Res Rev. 2022 Jan;38(1):e3465
pubmed: 33955644
Clin Infect Dis. 2021 Aug 2;73(3):e699-e709
pubmed: 33400782
Emerg Infect Dis. 2020 Jul;26(7):1478-1488
pubmed: 32267220
BMJ. 2021 May 13;373:n1088
pubmed: 33985964
Clin Chim Acta. 2021 Aug;519:60-63
pubmed: 33857476
Int J Obes (Lond). 2012 Aug;36(8):1072-7
pubmed: 22024641
Nature. 2020 Oct;586(7830):594-599
pubmed: 32998157
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
Lancet. 2021 Mar 20;397(10279):1057-1058
pubmed: 33640038
Med (N Y). 2021 Aug 13;2(8):979-992.e8
pubmed: 34223401
MMWR Morb Mortal Wkly Rep. 2021 Apr 02;70(13):495-500
pubmed: 33793460
Clin Microbiol Infect. 2021 Aug;27(8):1173.e1-1173.e4
pubmed: 33957273
Infection. 2022 Apr;50(2):439-446
pubmed: 34562263
Int J Infect Dis. 2021 Jan;102:136-143
pubmed: 33075538
Nature. 2020 Oct;586(7830):488-489
pubmed: 33082543
J Infect Dis. 2021 Jan 4;223(1):56-61
pubmed: 33128369
Nat Microbiol. 2021 Sep;6(9):1140-1149
pubmed: 34290390
Int J Environ Res Public Health. 2021 Oct 19;18(20):
pubmed: 34682719
Clin Infect Dis. 2021 May 4;72(9):1645-1648
pubmed: 32628750
Lancet. 2020 Mar 21;395(10228):922
pubmed: 32199474
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
J Allergy Clin Immunol. 2020 May;145(5):1309-1321
pubmed: 32386655
JAMA. 2021 May 11;325(18):1896-1898
pubmed: 33739374
Immunity. 2020 Apr 14;52(4):583-589
pubmed: 32259480